BioTelemetry Company Profile (NASDAQ:BEAT)

About BioTelemetry (NASDAQ:BEAT)

BioTelemetry logoBioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company's research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BEAT
  • CUSIP: N/A
  • Web: www.gobio.com
Capitalization:
  • Market Cap: $1 billion
  • Outstanding Shares: 32,360,000
Average Prices:
  • 50 Day Moving Avg: $35.68
  • 200 Day Moving Avg: $31.50
  • 52 Week Range: $15.25 - $39.20
P/E:
  • Trailing P/E Ratio: 20.81
  • Foreward P/E Ratio: 23.31
  • P/E Growth: 1.38
Sales & Book Value:
  • Annual Revenue: $211.19 million
  • Price / Sales: 4.75
  • Book Value: $5.11 per share
  • Price / Book: 6.07
Profitability:
  • EBIDTA: $41.34 million
  • Net Margins: 21.03%
  • Return on Equity: 18.75%
  • Return on Assets: 12.70%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 2.03%
  • Quick Ratio: 1.91%
Misc:
  • Average Volume: 478,847 shs.
  • Beta: 0.73
  • Short Ratio: 5.72
 

Frequently Asked Questions for BioTelemetry (NASDAQ:BEAT)

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry, Inc. (NASDAQ:BEAT) posted its quarterly earnings results on Tuesday, August, 8th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.21 by $0.02. The company had revenue of $58.10 million for the quarter, compared to analysts' expectations of $58.39 million. BioTelemetry had a return on equity of 18.75% and a net margin of 21.03%. The firm's revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 earnings per share. View BioTelemetry's Earnings History.

Where is BioTelemetry's stock going? Where will BioTelemetry's stock price be in 2017?

6 brokers have issued 1 year target prices for BioTelemetry's shares. Their forecasts range from $40.00 to $50.00. On average, they anticipate BioTelemetry's stock price to reach $45.75 in the next twelve months. View Analyst Ratings for BioTelemetry.

Are investors shorting BioTelemetry?

BioTelemetry saw a decrease in short interest in August. As of August 15th, there was short interest totalling 1,674,666 shares, a decrease of 33.7% from the July 31st total of 2,525,125 shares. Based on an average daily volume of 512,780 shares, the days-to-cover ratio is currently 3.3 days. Approximately 6.0% of the shares of the company are short sold.

Who are some of BioTelemetry's key competitors?

Who owns BioTelemetry stock?

BioTelemetry's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.44%), Vanguard Group Inc. (5.28%), Dimensional Fund Advisors LP (4.96%), Renaissance Technologies LLC (3.79%), Bank of New York Mellon Corp (3.60%) and Russell Investments Group Ltd. (3.39%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Peter Ferola and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Who sold BioTelemetry stock? Who is selling BioTelemetry stock?

BioTelemetry's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Vanguard Group Inc., Renaissance Technologies LLC, New York State Common Retirement Fund, Wells Fargo & Company MN, GSA Capital Partners LLP, EAM Investors LLC and Bank of Montreal Can. Company insiders that have sold BioTelemetry stock in the last year include Fred Broadway, George Hrenko and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.

Who bought BioTelemetry stock? Who is buying BioTelemetry stock?

BioTelemetry's stock was purchased by a variety of institutional investors in the last quarter, including Hood River Capital Management LLC, Russell Investments Group Ltd., Bank of New York Mellon Corp, Hodges Capital Management Inc., Castleark Management LLC, Stifel Financial Corp, Pembroke Management LTD and Monarch Partners Asset Management LLC. View Insider Buying and Selling for BioTelemetry.

How do I buy BioTelemetry stock?

Shares of BioTelemetry can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BioTelemetry stock can currently be purchased for approximately $31.00.


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioTelemetry (NASDAQ:BEAT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $45.75 (47.58% upside)

Analysts' Ratings History for BioTelemetry (NASDAQ:BEAT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017Off Wall StreetInitiated CoverageSellMediumView Rating Details
8/10/2017SidotiReiterated RatingBuy$42.00 -> $49.00LowView Rating Details
8/9/2017Dougherty & CoBoost Price TargetBuy$37.00 -> $40.00HighView Rating Details
7/19/2017Benchmark Co.Boost Price TargetBuy -> Buy$38.00 -> $44.00LowView Rating Details
7/14/2017Lake Street CapitalReiterated RatingBuy$35.00 -> $50.00HighView Rating Details
12/13/2016GabelliReiterated RatingBuyN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for BioTelemetry (NASDAQ:BEAT)
Earnings by Quarter for BioTelemetry (NASDAQ:BEAT)
Earnings History by Quarter for BioTelemetry (NASDAQ BEAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017$0.21$0.23$58.39 million$58.10 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.14$0.16$55.11 million$55.88 millionViewListenView Earnings Details
2/22/2017Q4 2016$0.18$0.23$53.75 million$53.96 millionViewListenView Earnings Details
11/2/2016Q316$0.18$0.21$52.92 million$53.10 millionViewN/AView Earnings Details
8/2/2016Q2$0.17$0.20$50.27 million$52.68 millionViewListenView Earnings Details
4/26/2016Q1$0.10$0.20$46.54 million$48.60 millionViewListenView Earnings Details
2/17/2016Q415$0.11$0.15$45.89 million$46.70 millionViewListenView Earnings Details
11/9/2015Q3$0.11$0.13$46.05 million$43.49 millionViewN/AView Earnings Details
8/6/2015Q2$0.09$0.12$45.75 million$44.81 millionViewListenView Earnings Details
5/6/2015Q115$0.02$0.06$43.80 million$43.40 millionViewListenView Earnings Details
2/19/2015Q414$0.06$0.05$43.40 million$43.70 millionViewListenView Earnings Details
10/30/2014Q214$0.01$0.06$42.00 million$43.00 millionViewListenView Earnings Details
7/31/2014Q114$0.01$0.02$40.95 million$42.70 millionViewListenView Earnings Details
5/6/2014Q413($0.02)($0.04)$38.40 million$37.16 millionViewListenView Earnings Details
2/26/2014Q313($0.04)$0.05$32.26 million$33.10 millionViewListenView Earnings Details
11/5/2013($0.05)($0.12)$32.79 million$31.90 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.02$27.50 million$32.10 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.09)$26.80 million$30.00 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.08)$26.49 million$27.00 millionViewN/AView Earnings Details
8/8/2012($0.04)($0.01)ViewN/AView Earnings Details
5/8/2012($0.12)($0.10)ViewN/AView Earnings Details
2/22/2012($0.13)($0.04)ViewN/AView Earnings Details
11/8/2011($0.09)($0.21)ViewN/AView Earnings Details
8/8/2011($0.06)($0.05)ViewN/AView Earnings Details
5/3/2011($0.15)($0.02)ViewN/AView Earnings Details
2/17/2011($0.16)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioTelemetry (NASDAQ:BEAT)
2017 EPS Consensus Estimate: $0.86
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.20$0.20$0.20
Q2 20171$0.20$0.20$0.20
Q3 20172$0.19$0.28$0.24
Q4 20171$0.22$0.22$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioTelemetry (NASDAQ:BEAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioTelemetry (NASDAQ:BEAT)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 77.60%
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)
Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Robert J. RubinDirectorSell15,000$28.14$422,100.00View SEC Filing  
3/20/2017Fred BroadwaySVPSell3,429$26.90$92,240.10View SEC Filing  
2/27/2017George HrenkoSVPSell126,043$25.95$3,270,815.85View SEC Filing  
2/21/2017Fred BroadwaySVPSell8,070$24.81$200,216.70View SEC Filing  
9/19/2016George HrenkoSVPSell1,061$18.50$19,628.50View SEC Filing  
9/13/2016Heather C GetzCFOSell5,866$18.23$106,937.18View SEC Filing  
9/13/2016Joseph H CapperInsiderSell26,847$18.23$489,420.81View SEC Filing  
9/13/2016Peter FerolaGeneral CounselSell4,352$18.23$79,336.96View SEC Filing  
9/9/2016Fred BroadwaySVPSell3,146$17.84$56,124.64View SEC Filing  
9/8/2016George HrenkoSVPSell3,491$18.06$63,047.46View SEC Filing  
9/8/2016Heather C GetzCFOSell2,979$18.10$53,919.90View SEC Filing  
9/8/2016Joseph H CapperInsiderSell13,632$18.10$246,739.20View SEC Filing  
9/8/2016Peter FerolaGeneral CounselSell2,210$18.10$40,001.00View SEC Filing  
9/7/2016Daniel WisniewskiSVPSell9,225$18.51$170,754.75View SEC Filing  
9/7/2016Heather C GetzCFOSell18,945$18.52$350,861.40View SEC Filing  
9/7/2016Joseph H CapperInsiderSell86,681$18.52$1,605,332.12View SEC Filing  
9/7/2016Peter FerolaGeneral CounselSell14,053$18.52$260,261.56View SEC Filing  
9/6/2016Fred BroadwaySVPSell4,662$18.28$85,221.36View SEC Filing  
9/6/2016Heather C GetzCFOSell6,686$18.29$122,286.94View SEC Filing  
9/6/2016Joseph H CapperCEOSell30,595$18.29$559,582.55View SEC Filing  
9/6/2016Peter FerolaGeneral CounselSell4,960$18.29$90,718.40View SEC Filing  
9/2/2016Fred BroadwaySVPSell4,466$18.75$83,737.50View SEC Filing  
9/2/2016Heather C GetzCFOSell6,547$18.75$122,756.25View SEC Filing  
9/2/2016Joseph H CapperCEOSell29,953$18.75$561,618.75View SEC Filing  
9/2/2016Peter FerolaGeneral CounselSell4,856$18.75$91,050.00View SEC Filing  
9/1/2016Fred BroadwaySVPSell7,525$19.25$144,856.25View SEC Filing  
9/1/2016Heather C GetzCFOSell10,408$18.59$193,484.72View SEC Filing  
9/1/2016Joseph H CapperInsiderSell47,622$18.59$885,292.98View SEC Filing  
9/1/2016Peter FerolaGeneral CounselSell7,722$18.59$143,551.98View SEC Filing  
8/30/2016Fred BroadwaySVPSell12,121$19.07$231,147.47View SEC Filing  
8/30/2016Heather C GetzCFOSell17,482$19.07$333,381.74View SEC Filing  
8/30/2016Joseph H CapperInsiderSell79,986$19.07$1,525,333.02View SEC Filing  
8/30/2016Peter FerolaGeneral CounselSell12,970$19.07$247,337.90View SEC Filing  
8/25/2016Fred BroadwaySVPSell5,877$19.16$112,603.32View SEC Filing  
8/25/2016Heather C GetzCFOSell8,477$19.16$162,419.32View SEC Filing  
8/25/2016Joseph H CapperInsiderSell38,785$19.16$743,120.60View SEC Filing  
8/25/2016Peter FerolaGeneral CounselSell6,289$19.16$120,497.24View SEC Filing  
8/24/2016George HrenkoSVPSell7,473$20.11$150,282.03View SEC Filing  
8/24/2016Heather C GetzCFOSell8,778$20.11$176,525.58View SEC Filing  
8/24/2016Joseph H CapperCEOSell40,160$20.11$807,617.60View SEC Filing  
8/24/2016Peter FerolaGeneral CounselSell6,512$20.11$130,956.32View SEC Filing  
8/23/2016George HrenkoSVPSell3,165$20.67$65,420.55View SEC Filing  
8/23/2016Heather C GetzCFOSell3,717$20.67$76,830.39View SEC Filing  
8/23/2016Joseph H CapperCEOSell17,008$20.67$351,555.36View SEC Filing  
8/23/2016Peter FerolaGeneral CounselSell2,758$20.67$57,007.86View SEC Filing  
8/22/2016George HrenkoSVPSell4,149$20.85$86,506.65View SEC Filing  
8/22/2016Heather C GetzCFOSell4,874$20.85$101,622.90View SEC Filing  
8/22/2016Joseph H CapperCEOSell22,298$20.85$464,913.30View SEC Filing  
8/22/2016Peter FerolaGeneral CounselSell3,616$20.85$75,393.60View SEC Filing  
8/19/2016Daniel WisniewskiSVPSell9,025$20.96$189,164.00View SEC Filing  
8/19/2016Heather C GetzCFOSell9,026$20.96$189,184.96View SEC Filing  
8/19/2016Joseph H CapperInsiderSell9,049$20.96$189,667.04View SEC Filing  
8/19/2016Peter FerolaGeneral CounselSell9,035$20.96$189,373.60View SEC Filing  
5/9/2014Ronald AhrensDirectorBuy6,000$7.37$44,220.00View SEC Filing  
11/12/2013Ronald AhrensDirectorBuy5,000$11.73$58,650.00View SEC Filing  
11/12/2012Ronald A AhrensDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/5/2012Joseph H CapperCEOBuy23,540$2.25$52,965.00View SEC Filing  
8/31/2012Joseph H CapperCEOBuy2,600$2.28$5,928.00View SEC Filing  
8/29/2012Joseph H CapperCEOBuy10,800$2.30$24,840.00View SEC Filing  
8/28/2012Joseph H CapperCEOBuy1,300$2.19$2,847.00View SEC Filing  
8/27/2012Joseph H CapperCEOBuy1,600$2.12$3,392.00View SEC Filing  
8/23/2012Joseph H CapperCEOBuy9,600$2.08$19,968.00View SEC Filing  
8/20/2012Joseph H CapperCEOBuy14,160$1.97$27,895.20View SEC Filing  
8/17/2012Joseph H CapperCEOBuy9,800$2.10$20,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioTelemetry (NASDAQ:BEAT)
Latest Headlines for BioTelemetry (NASDAQ:BEAT)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to BioTelemetry, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 9:30 PM
finance.yahoo.com logoBioTelemetry, Inc. – Value Analysis (NASDAQ:BEAT) : September 19, 2017
finance.yahoo.com - September 19 at 9:30 PM
nasdaq.com logoBioTelemetry Enters Oversold Territory (BEAT)
www.nasdaq.com - September 18 at 4:49 PM
finance.yahoo.com logoBioTelemetry, Inc. breached its 50 day moving average in a Bearish Manner : BEAT-US : September 18, 2017
finance.yahoo.com - September 18 at 4:49 PM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 16 at 4:54 PM
nasdaq.com logoNotable Friday Option Activity: LOW, GRA, BEAT - Nasdaq
www.nasdaq.com - September 15 at 9:54 PM
finance.yahoo.com logoDoes BioTelemetry Inc’s (BEAT) PE Ratio Warrant A Buy?
finance.yahoo.com - September 15 at 4:50 PM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) Now Covered by Analysts at Off Wall Street
www.americanbankingnews.com - September 15 at 11:48 AM
finance.yahoo.com logoCan BioTelemetry (BEAT) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - August 30 at 5:44 PM
americanbankingnews.com logoSignal Genetics (MGEN) vs. BioTelemetry (BEAT) Critical Contrast
www.americanbankingnews.com - August 30 at 12:18 PM
americanbankingnews.com logoShort Interest in BioTelemetry, Inc. (BEAT) Drops By 33.7%
www.americanbankingnews.com - August 29 at 1:06 AM
nasdaq.com logoWhy Biotelemetry (BEAT) Could Be an Impressive Growth Stock - Nasdaq
www.nasdaq.com - August 23 at 9:37 PM
finance.yahoo.com logoETFs with exposure to BioTelemetry, Inc. : August 21, 2017
finance.yahoo.com - August 23 at 4:37 PM
finance.yahoo.com logoWhy Biotelemetry (BEAT) Could Be an Impressive Growth Stock
finance.yahoo.com - August 23 at 4:37 PM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 22 at 4:36 PM
nasdaq.com logoTrump & Terror Hint at Market Pullback: 5 Ultra-Safe Picks - Nasdaq
www.nasdaq.com - August 22 at 2:29 AM
nasdaq.com logoHere's Why Investors Should Buy BioTelemetry (BEAT) Now - Nasdaq
www.nasdaq.com - August 22 at 2:29 AM
americanbankingnews.com logoBioTelemetry (BEAT) vs. Signal Genetics (MGEN) Financial Review
www.americanbankingnews.com - August 22 at 12:18 AM
zacks.com logoHere's Why Investors Should Buy BioTelemetry (BEAT) Now
www.zacks.com - August 21 at 4:27 PM
finance.yahoo.com logoTrump & Terror Hint at Market Pullback: 5 Ultra-Safe Picks
finance.yahoo.com - August 21 at 4:27 PM
finance.yahoo.com logoHere's Why Investors Should Buy BioTelemetry (BEAT) Now
finance.yahoo.com - August 21 at 4:27 PM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) Expected to Earn FY2017 Earnings of $1.00 Per Share
www.americanbankingnews.com - August 21 at 5:34 AM
americanbankingnews.com logoHead-To-Head Survey: BioTelemetry (BEAT) vs. Signal Genetics (MGEN)
www.americanbankingnews.com - August 21 at 2:10 AM
americanbankingnews.com logoHead to Head Review: Signal Genetics (MGEN) and BioTelemetry (BEAT)
www.americanbankingnews.com - August 19 at 6:34 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for BioTelemetry, Inc.'s Q3 2017 Earnings (BEAT)
www.americanbankingnews.com - August 18 at 7:20 AM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) Upgraded to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - August 17 at 12:08 AM
zacks.com logoBioTelemetry Hits a 52-Week High: What's Driving the Stock?
www.zacks.com - August 16 at 5:02 PM
finance.yahoo.com logoBioTelemetry Hits a 52-Week High: What's Driving the Stock?
finance.yahoo.com - August 16 at 5:02 PM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - August 11 at 9:04 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for BioTelemetry, Inc.'s FY2017 Earnings (NASDAQ:BEAT)
www.americanbankingnews.com - August 11 at 11:18 AM
finance.yahoo.com logoBioTelemetry, Inc. :BEAT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 5:38 PM
americanbankingnews.com logoSidoti Reiterates Buy Rating for BioTelemetry, Inc. (NASDAQ:BEAT)
www.americanbankingnews.com - August 10 at 2:39 PM
finance.yahoo.com logoBioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates
finance.yahoo.com - August 9 at 4:41 PM
finance.yahoo.com logoEdited Transcript of BEAT earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 4:41 PM
americanbankingnews.com logoDougherty & Co Boosts BioTelemetry, Inc. (BEAT) Price Target to $40.00
www.americanbankingnews.com - August 9 at 1:30 PM
globenewswire.com logoBioTelemetry, Inc. Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 2:23 AM
americanbankingnews.com logoBioTelemetry, Inc. (NASDAQ:BEAT) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 9:30 PM
finance.yahoo.com logoBioTelemetry posts 2Q profit
finance.yahoo.com - August 8 at 9:16 PM
finance.yahoo.com logoBioTelemetry, Inc. Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 4:13 PM
bizjournals.com logoStock Performance Review on Medical Laboratories & Research Industry -- Cancer Genetics, BioTelemetry, Organovo, and Bruker
www.bizjournals.com - August 2 at 3:22 AM
finance.yahoo.com logoETFs with exposure to BioTelemetry, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 5:20 PM
nasdaq.com logoBioTelemetry, Inc. to Release Second Quarter 2017 Earnings ... - Nasdaq
www.nasdaq.com - July 31 at 8:25 PM
feeds.benzinga.com logoBioTelemetry, Inc. to Release Second Quarter 2017 Earnings Results on August 8, 2017
feeds.benzinga.com - July 31 at 8:59 AM
americanbankingnews.com logoShort Interest in BioTelemetry, Inc. (NASDAQ:BEAT) Grows By 48.6%
www.americanbankingnews.com - July 29 at 7:01 AM
nasdaq.com logoFirst Week of November 17th Options Trading For BioTelemetry (BEAT)
www.nasdaq.com - July 28 at 5:50 PM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 28 at 4:39 PM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) to Release Earnings on Monday
www.americanbankingnews.com - July 24 at 8:04 AM
americanbankingnews.com logoBioTelemetry, Inc. (BEAT) Price Target Increased to $44.00 by Analysts at Benchmark Co.
www.americanbankingnews.com - July 19 at 10:32 AM
nasdaq.com logoBioTelemetry, Inc. (BEAT) in Focus: Stock Moves 6.5% Higher - Nasdaq
www.nasdaq.com - July 17 at 4:45 PM
finance.yahoo.com logoBioTelemetry, Inc. (BEAT) in Focus: Stock Moves 6.5% Higher
finance.yahoo.com - July 17 at 12:29 PM

Social

Chart

BioTelemetry (BEAT) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff